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Objective: Prostate cancer continues to be one of the highest incident cancers among men. 
Reducing serum testosterone with androgen deprivation therapy (ADT) is a common effective 
treatment. While well demonstrated for cancer suppression, there are numerous adverse effects 
caused by ADT that can contribute to short- and long-term prognosis. Increased levels of physical 
activity (PA) during treatment may reduce these side effects, however uptake of PA is low. The 
purpose of this review is to identify and evaluate current literature on strategies to promote and 
increase the levels of PA in patients with prostate cancer undergoing ADT. 
Data sources: Electronic databases including CINAHL, MEDLINE, PsychINFO, Scopus, and grey 
literature were searched using Google scholar up until April 2020. 
Conclusion: At present the most appropriate modes and dosages of PA for specific ADT toxicities is 
not known. It is established that some PA in the form of exercise, whether aerobic or resistance, is 
better than being sedentary for improvements in physical health, but beyond this prescription 
specifics have not been established. Further research is required to understand the impact of PA on 
the mental and physical health of prostate cancer men undergoing ADT. 
Implications for Nursing Practice: Being physically active and avoiding sedentary behaviour is 
important for men with prostate cancer undergoing ADT, especially the implementation of strength 
training. Physical activity in the form of exercise can assist in reducing the adverse physical side 
effects in the short- and long-term, with limited understanding of the effects on mental health. 
Physical activity improves mental health outcomes across populations, which may also translate to 
men with prostate cancer, although further research is required. An important strategy to improve 
PA within the prostate cancer population is to provide an early referral to an exercise professional 
such as an Accredited Exercise Physiologist/Clinical Exercise Physiologist or Physical 
Therapist/Physiotherapist and is supported by research as best practice for people affected by 
cancer undergoing active treatment. 









Worldwide, prostate cancer is the second leading malignancy (after lung cancer) in men with 
1,276,106 new cases diagnosed in 2018 [1], and a higher prevalence seen in developed countries [2].  
Increased risk of prostate cancer and mortality is linked with increasing age, with the average age at 
diagnosis of 66 years [1]. There is currently no evidence of how to prevent prostate cancer, though 
some research suggests that it is possible to lower the risk by changing behavioural factors such as 
increasing levels of physical activity (PA) and in particular avoid being sedentary [3]. Although 
epidemiological studies have shown that increased levels of PA may prevent prostate cancer and 
improve survival after diagnosis [4], low levels of PA and sedentary behaviour is widespread across 
the globe, which includes men with prostate cancer [5-7]. Many gaps remain in the knowledge to 
better serve cancer survivors, as well as best practice for exercise and health care professionals [8] 
to improve the clinical outcomes for patients diagnosed with prostate cancer.  
The sex hormone, testosterone, is essential for prostate cancer cell growth in hormone 
responsive cancers. The aim of androgen deprivation therapy (ADT) treatment is to reduce systemic 
testosterone levels or prevent testosterone binding to the androgen receptor. Resistance based 
exercise has not been shown to increase levels of testosterone in patients undergoing ADT [9]. 
Chemical castration slows the progression of prostate cancer and can prolong life and palliate 
symptoms [10].  Castration can be achieved pharmacologically using luteinizing-hormone-releasing 
hormone (LHRH) agonists, LHRH antagonists, anti-androgens or oestrogens, or surgically with 
bilateral subcapsular orchidectomy, see Table 1.  Common side-effects for ADT include: 
psychological effects: mood disturbance, cognitive impairment, difficulties with self-image and 
masculinities; physical effects such as hot flushes, osteoporosis, fatigue, sexual dysfunction, and 
changes in muscle mass; and adiposity. 
Aerobic and resistance exercise may impact cancer signalling pathways, potentially reducing 
tumour growth [11], muscle wasting and the physical side effects of ADT [12 13]. The maintenance 
of skeletal muscle is essential to ensure function and movement, strength and breathing, glucose 
and insulin management potentially via hormonal balance mechanisms [14] as well as various anti-
tumour cytokine and immunological mechanisms [15 16]. Sarcopenia (muscle wasting) is 
orchestrated by a network of specific signalling pathways [17] that cause an imbalance in muscle 
protein synthesis and degradation [18]. The loss of lean body mass seen in men receiving ADT is 
often associated with increased fat mass, which is referred to as sarcopenic obesity [19]. An 
appropriate combination of aerobic and resistance exercise could regulate this signalling pathway, 
causing a slowing of, or even reversing, muscle atrophy and potentially preventing or minimising fat 
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gain. Impacting this system by the early introduction of resistance exercise could most importantly 
minimise the loss of muscle function in patients with prostate cancer, particularly for older men on 
ADT who experience greater levels of muscle mass and function loss and more debilitating 
treatment related side effects. Although the evidence to support improvements in lean muscle mass 
is limited [20], the maintenance or slowing of cachexia and increased muscle performance could be 
enhanced by improving neural pathways and neuromuscular function with resistance based exercise 
[21 22] resulting in improvements in physical strength and quality of life.  
The mechanisms of prostate carcinogenesis consist of both behavioural and environmental 
factors [23]. After years of controversial research studies [24 25], it has recently been established 
that sedentary behaviour, overweight or obesity (which are not always mutually inclusive) can 
increase risk of aggressive advanced prostate cancer [26 27]. Being overweight or obese may cause 
changes in several mechanisms including altered endocrine status, increased sympathetic nervous 
system activity, increased intra-abdominal pressure, increased inflammation and oxidative stress, all 
of which have been linked to benign hyperplasia prostate cancer [28-32]. Because prostate cancer 
treatment  can also impact different mechanisms such as reduced testosterone and androgens, 
insulin resistance, unfavourable adipokine secretion caused by inflammation, being obese and the 
side effects of prostate cancer treatment can increase the risk of the development of higher-grade 
prostate cancer [33-35]. 
Androgen deprivation therapy increases the risk of metabolic diseases including 
cardiovascular, type 2 diabetes, hypertension and obesity impacting the physical and mental health 
of men with prostate cancer. Due to the hypogonadal state caused by ADT, men undergo physical 
and psychological side effects including atrophy of muscle and bone tissues decreasing physical and 
metabolic function [13], and psychological distress related to changes in masculinity [14]. Patients 
receiving ADT have an increased risk of depression [10], which is also linked to clinical and 
demographic factors such as older age, comorbidities and a concurrent history of depression [11]. 
Unfortunately, the older the patient the worse the increased loss of physical function and 
psychological distress, because of the already present age-related muscle and bone loss [13]. 
Emerging evidence shows that PA improves physical functioning for men previously treated 
with ADT [36]. Physical activity in the form of aerobic and progressive resistance exercise has been 
shown to improve cardiorespiratory fitness, strength and slow muscle wasting [11] and it has been 
reported that highly targeted exercise can slow bone loss [12]. The effect of increased levels of both 
forms of PA is associated with additional positive physiological, functional and psychological 
adaptations across a number of healthy, ageing and chronic diseased populations [13]. These 
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benefits are likely to be translated to patients with prostate cancer as stronger evidence develops 
[14 15].  
 Aerobic and progressive resistance exercise have recently been endorsed by the American 
College of Sports Medicine (ACSM), Exercise and Sports Science Australia (ESSA) and the Clinical 
Oncology Society of Australia (COSA) for patients with all cancers [37-39], to reduce or alleviate 
adverse side effects of cancer treatments, enhance treatment effectiveness, reduce risk of cancer 
specific mortality and recurrence as well as ameliorate other chronic diseases exacerbated by cancer 
and its treatment. They recommend both aerobic (150 minutes per week) and resistance based (two 
or more sessions per week) exercise as a generic dosage of exercise in relatively healthy individuals. 
However, currently there are limited randomised controlled trials providing strong indication of the 
optimal mode and intensity required to improve the physical and mental health of men with 
prostate cancer. General guidelines are based on research that has found that increased levels of PA 
can reduce rates of cancer recurrence and improve survival, but the specific effects of different 
types of PA modalities (such as aerobic and resistance exercise) on physical and mental health in 
prostate cancer are currently not well understood [39-41]. Some evidence reports that that both 
resistance and aerobic exercise may illicit the greatest effect and that resistance training improves 
strength and maintains muscle mass, despite the catabolic drive of ADT treatment for prostate 
cancer [42 43]. Exercise treatment or strategies, including the optimal mode and dosage of PA, how 
to get patients to commence and adhere to an exercise program to improve levels of PA and how to 
pragmatically implement these programs into the health system are not known, but are urgently 
needed to establish optimal treatment pathways for men with prostate cancer undergoing ADT. 
Given the importance and potential of PA and exercise to improve outcomes for men on ADT for 
prostate cancer we will discuss the strategies to promote and improve PA levels and to inform 
clinical service delivery to help improve physical and mental health outcomes in men affected by 
prostate cancer receiving ADT. We will do this by discussing clinical management, barriers to PA for 
patients and health professionals, general cancer evidence-based PA guidelines currently available 








Table 1. Androgen deprivation therapy (ADT) for prostate cancer [44] 
Surgical castration using bilateral orchiectomy • Performed under local anaesthesia 
• less than 12 hours to achieve decline in 
testosterone level and induce a hypogonadal 
status 
• does not allow for intermittent treatment. 
• No testosterone flare 
Oestrogens • Mechanisms of action in management of 
prostate cancer include: 
o down regulation of LHRH secretion 
o androgen inactivation 
o direct suppression of Leydig cell function. 
• Good response rates associated with oestrogen 
use in castrate-refractory prostate cancer. 
• Precluded as standard first-line treatment due 
to cardiotoxicity. 
Luteinizing hormone-releasing hormone (LHRH) agonists • Synthetic analogues of LHRH. 
• Chronic exposure to LHRH agonists results in the 
downregulation of LHRH-receptors, suppressing 
luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) secretion and therefore 
testosterone production. The castration level is 
usually obtained within 2-4 weeks.  
• A ‘testosterone surge’ or ‘flare up’ phenomenon 
may occur after the first dose and might lead to 
detrimental effects such as increased bone pain, 
acute bladder outlet obstruction, obstructive 
renal failure, spinal cord compression, and fatal 
cardiovascular events due to hypercoagulation 
status. 
Luteinizing hormone-releasing hormone (LHRH) 
antagonists 
• LHRH antagonists bind immediately and 
competitively to LHRH receptors in the pituitary 
gland leading to rapid decrease in LH, FSH and 
testosterone levels without any flare. 
• Use limited by lack of long-acting formulation. 
Anti-androgens • Compete with androgens at the receptor level 
• Oral compounds classified as: 
o steroidal, e.g. cyproterone acetate 




o non-steroidal or pure, e.g. nilutimide, 
flutamide and bicalutamide. 
 
Clinical management 
Health promotion is a key component of cancer survivorship care. Regular follow-up visits 
with survivors of cancer provide a prime opportunity for healthcare providers to encourage 
important health behaviours, like PA, for the maintenance of health-related quality of life (HRQOL), 
physical and psychological functioning in older adulthood. Further, targeted exercise to manage 
disease and treatment related side effects is increasingly being implemented in best-practice care of 
people affected by cancer [39]. Integrated care is becoming increasingly accepted to overcome 
fragmentation of patient management to provide a consistent approach across the multidisciplinary 
team, with the specialist nurse at the hub of cancer care [45]. Physical activity as well as prescribed 
aerobic and resistance exercise are important components of the management of cancer, other 
comorbid conditions, and maintenance of physical and psychological functioning [46-48] and 
particularly relevant for men receiving ADT.  
 
Barriers to physical activity in prostate cancer patients 
There are few studies examining the barriers to PA and exercise after prostate cancer 
treatment. Links can be made from research on barriers to commencing PA in the age group and 
with men who have other health concerns [49], or other cancer treatments [50]. Psychosocial stress 
and distress are common amongst all cancer patients [51]. While prostate cancer patients were 
found to have lower distress scores than other cancers, fatigue, pain, depression, and anxiety are all 
barriers to undertaking PA. Carlson et al [51] found that men with prostate cancer were much less 
likely to seek psychosocial care than any other type of cancer. In a study of 193 prostate cancer 
survivors, being busy, or lacking willpower as well as access to fitness facilities or exercise equipment 
were barriers to commencing or continuing PA [52]. Throughout treatment, these men reduced their 
barriers to PA by 36%, increasing their PA time by an average of 43 minutes over 12 months of a 
home based PA intervention [53]. Urinary function and bowel bother post prostate cancer treatment 
are also frequently seen as barriers to commencing PA. At 12 and 52 months post radical 
prostatectomy (RP) (often the first line treatment with subsequent ADT) or external beam radiation 
(EBR) urinary bother was found to be a concern in 8% and 4% post RP and 2% post ERB. Bowel 
bother occurred in 2% post PR and 11% post EBR at 52 months [54].  
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Worldwide, different PA participation barriers are reported by prostate cancer patients, 
depending on the country, for example in Australia most health care professionals (Doctors and 
Nurses) do not discuss the importance of PA and exercise with their patients [55]. Two thirds of the 
population are sedentary [56], and this is reflected within the prostate cancer population. Education 
and behaviour change strategies are needed to improve referrals and the level of uptake of PA 
within the population. A referral to a clinical psychologist (as part of the multidisciplinary team) may 
be considered to help with treatment and PA adherence and the psychological barriers experienced 
by men receiving ADT.  
There are challenges within health systems because exercise as medicine has a financial cost 
(albeit not as great as the cost of diseases which could be prevented by PA) which is not adequately 
supported by medical/Medicare systems and not uniformly available across countries such as 
Australia. The UK offer free exercise programming through the national health service (NHS), this 
opportunity removes the barrier of not having access to a program to improve PA. A review by Fox 
et al. [57] from the UK suggested that better coordination of multidisciplinary teams could facilitate 
improved levels of PA. Enabling a more comprehensive approach and well timed inventions and 
access to highly individualised support, including group exercise classes, are important facilitators to 
improve health outcomes for men with prostate cancer undergoing ADT [57]. Similarly, within 
Australia, men with prostate cancer can receive up to five consultations per calendar year with an 
Accredited Exercise Physiologist as part of their chronic disease management plan during which 
health and fitness assessment is completed as well as prescription of a tailored exercise program 
[39]. Health care professionals and men on ADT are reportedly in favour of PA and exercise 
programs as part of their cancer care, but the need for financial support is reportedly a major barrier 
to the provision of best practice [58]. 
 
Barriers to discussing physical activity by healthcare professionals 
Very little has been written on the barriers that healthcare professionals encounter to 
discussing PA in men who are undergoing treatment for prostate cancer. One study explored the 
barriers to referral to physiotherapy for management of post prostatectomy incontinence [59]. The 
findings identified that social or professional role and beliefs of the healthcare professional’s 
capabilities, often stopped a health care professional from discussing management of incontinence 
with patients, thereby preventing timely referrals. Lack of resources and funding were also reported 
to be a barrier, where health care services were stretched and at full capacity, especially in the 
public sector, lacking resources and time to have the conversation about the importance of PA.  
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Santa Mina et al. [60] explored enablers and barriers of the delivery of a cancer exercise 
program among healthcare professionals. Barriers experienced were lack of funding and lack of 
physician support. Most healthcare professionals reportedly acknowledge the value of PA and agree 
that discussing PA with the cancer patient is part of their role, however, the majority of the 
recommendations when given do not align with the current guidelines [61].  In Australia, despite our 
national health system, Medicare, providing support for cancer patients to receive consultations 
with an Accredited Exercise Physiologist, the pathway is rarely engaged by healthcare professionals 
[39].  The evidence for the safety and efficacy of targeted exercise prescriptions for prostate cancer 
management is compelling and increasingly being integrated into best practice, but barriers (cost, 
access and behaviour change) for patients remain [37]. Optimising education about the benefits of 
PA for patients and healthcare professionals, as well as improvements in logistical strategies for the 
referral processes, would improve the uptake of PA and exercise programs for men undergoing ADT. 
 
Evidence-based guidelines and strategies to promote PA 
The ACSM, ESSA and COSA encourage Oncologists and Nurses to refer men affected by 
prostate cancer to Qualified Exercise Professionals such as Accredited Exercise Physiologists / Clinical 
Exercise Physiologists and Physical Therapists / Physiotherapists with experience in cancer care for 
the right advice on what PA and exercise is appropriate for the individual patient before, during and 
after treatment. Generally, both aerobic and resistance exercise should be considered as part of the 
multi model approach to care for men with prostate cancer to reduce the detrimental effects of 
ADT, however the balance of mode and the actual dosage needs to be tailored to the individual 
patient [39 62], with special considerations feeding into the clinical rationale for each patient. Most 
importantly, prolonged sedentary behaviour irrespective of PA levels [63] may be linked to 
aggressive prostate cancer through mechanisms associated with obesity [27 64]. A holistic approach 
towards men with prostate cancer and potentially their families and carers are needed to improve 
the multitude of undesirable outcomes which can be experienced by patients [62].  Interventions 
most likely will encompass strategies for improved strength, mental health and significant fat loss 
requiring a clinical psychologist, nutritionist or dietitian on the multidisciplinary care team. 
 
Physical activity and Mental Health 
Physical activity in the form of exercise has in general demonstrated to be associated with 
better mental health; however, the results are variable in terms of the extent to which amount of 
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exercise and other demographic variables may influence these effects [65]. Androgen deprivation 
therapy is associated with higher 3-year cumulative incidences of depression with a 23% increased 
risk ratio [66]. It was also shown in a large study of elderly men with prostate cancer that ADT 
increased the risk of depression [67]. There appears to be an increased risk of both depression and 
cognitive impairment for men receiving ADT, and it seems that even today the optimal treatment for 
either is unclear. Considering approximately half of men diagnosed with prostate cancer will receive 
ADT within the first year of diagnosis [68], it leaves a large cohort of men at clinical risk of depression 
and cognitive decline with no proven treatment options. Not only are men dealing with the impact 
of treatment to their mental health, there are also numerous other changes in their overall health 
that are associated. These include as mentioned above, decreases in cardiovascular health, 
decreases in strength, increases in fat composition and decreases in bone density, along with 
decreases in libido, erections, and changes in insulin sensitivity [69]. Physical activity and exercise 
have been shown with good evidence to improve physical health (cardiovascular and muscle 
strength) in men undergoing ADT and it is especially important for men to participate in exercise if 
they are on long term ADT treatments [70]. Targeted exercise prescription may be required to 
improve mental health outcomes with the inclusion of both aerobic and resistance exercise 
integrated at the same time as commencing ADT. Although experts suggest that this would be 
advantageous for these men, the evidence is limited on the impact of exercise on mental health 
outcomes [71]. Exercise when beginning ADT may be preferable to reduce treatment toxicities 
because it aids in preventing decline rather than relying on it later as a rehabilitative intent to 
reverse treatment side effects, which if prolonged negatively affects mental health [22 72].  
Situational psychological changes may have a greater impact on the psychological wellbeing 
of men with prostate cancer than biological changes and the complexity of adding ADT may further 
disrupt balance for these men. This imbalance can contribute to further complications in men’s 
relationships due to the exacerbation of changes to body image, cognitive decline, decreased libido 
and erections [73]. Partner psychological distress due to these changes have been reported to be as 
high or even higher that the patients themselves [45 74]. Treatment options for men with prostate 
cancer to reduce the physical and mental health burden of the side effects of ADT treatment should 
also be considered for their partners. It should include a range of professions working together to 
individually prescribe what is needed on a case by case basis, including psychological therapy. The 
inclusion of PA programs and/or targeted exercise to minimise treatment side effects would be 
optimal for patients undergoing ADT. Future research should look at a multi-disciplinary team 
approach to ensure that behaviour change and education strategies are successful for both men 
affected by prostate cancer and their partners. Furthermore, impending studies are required to 
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identify optimal treatments for both the physical and mental health needs of men with prostate 
cancer receiving ADT. At present the most appropriate modes and dosages of exercise for specific 
ADT toxicities is not known. It is well established that some exercise, whether aerobic or resistance, 
is better than being sedentary, the evidence for resistance training to improve strength in prostate 
cancer patients undergoing ADT is building, but beyond this prescription specifics have not been 
established. We must also ultimately demonstrate a survival benefit for exercise in a randomised 
control trial to convince patients, clinicians, and governments that participation and financial 
support for quality and effective exercise programs should be an essential component of best 
practice care of men with prostate cancer undergoing ADT.  
 
Nursing implications 
The Prostate Cancer Specialist Nurse provides a hub of survivorship care across the entire 
cancer care continuum embedded within the wider multidisciplinary team [75], with clear role 
distinction and overlaps with other disciplines. For example, the Urological Surgeon will only be 
involved with the treatment of radical surgery itself, but the specialist nurse can further assist 
treatment decisions through information and support. Whereas, often, the specialist nurse will take 
the lead on managing the after effects of treatment and symptom management and providing timely 
referrals to Health Psychologists, Sex Therapists, and Qualified Exercise Professionals such as 
Accredited Exercise Physiologists / Clinical Exercise Physiologists and Physical Therapists / 
Physiotherapists with experience in cancer care.  Therefore, it is essential that nurses advocate and 
support for all patients to be physically active and trigger timely referrals to appropriately trained 
professionals.  Specialist Nurses provide clinical leadership which can help to facilitate and develop 
clinical pathways for timely referral for tailored exercise programmes for men affected by prostate 
cancer [62]. Future cancer pathways must support the implementation of exercise guidelines and 
should serve as a model of enhanced care delivery to increase the health and well-being of people 
with cancer. 
 
Key Points  
• Androgen deprivation therapy (ADT) increases risk of adverse metabolic and musculoskeletal 
effects impacting physical and mental health of men with prostate cancer 
• Promoting participation in a combination of aerobic and resistance exercise benefits the 
physical health of men with prostate cancer undergoing ADT 
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• Training for muscle size and strength with the use of resistance exercise is key to maintain 
and improve functional capacity in men undergoing ADT 
• Increases in physical activity may improve the mental health of men undergoing ADT, 
however more research is needed  
• An early referral to an exercise professional may improve treatment outcomes and the 
physical health of men with prostate cancer undergoing ADT 
 
Conclusion 
Future research is needed to understand current PA and exercise behaviours in men with 
prostate cancer undergoing ADT, especially an understanding of the impact of exercise on patients’ 
mental health. Targeted PA in the form of exercise has been shown to improve quality of life, fitness, 
fatigue, and muscular strength in men with prostate cancer and should be considered as part of the 
treatment plan for men undergoing ADT. Conclusions from this review are that promoting the 
importance of resistance training for men undergoing ADT which will improve physical and 
potentially mental health. Also promoting participation in PA could reduce the severity of toxicities 
experienced during treatment, even though the optimal intensity and dosage of prescription to 
improve these outcomes is currently unknown. Best practice for people affected by cancer 
undergoing active treatment should include person-centred timely referrals to wider members of 
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